Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line

被引:11
|
作者
Gnanasekaran, Krishna Kumar [1 ]
Benbrook, Doris Mangiaracina [2 ]
Nammalwar, Baskar [1 ]
Thavathiru, Elangovan [2 ]
Bunce, Richard A. [1 ]
Berlin, K. Darrell [1 ]
机构
[1] Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73104 USA
基金
美国国家科学基金会;
关键词
Second generation flexible heteroarotinoids; Flex-Hets; SHetA2; series; Anti-cancer agents; Ovarian cancer; RETINOIC ACID RECEPTOR; INDUCE APOPTOSIS; ANTITUMOR AGENT; X-RECEPTOR; HETEROAROTINOIDS; SHETA2; ANTICANCER; MITOCHONDRIA; SUFFICIENT; TOXICITY;
D O I
10.1016/j.ejmech.2015.03.070
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Flexible Heteroarotinoids (Flex-Hets) are a class of substituted di-aryl compounds that exhibit potent anti-cancer activity without toxicity. They were derived from the more conformationally restricted, 2-atom linker Hets by substitution of the 2-atom linker with a 3-atom urea or thiourea linker, which conferred more potent inhibitory activity against cancer cell lines. The objectives of this structure activity relationship (SAR) study were to determine if a 4-atom acrylamide linker and various substitutions on the terminal aryl ring altered the anti-cancer activity of these second generation Flex-Het compounds compared to the parent Flex-Het compound, SHetA2, which has a thiourea linker and a nitro substituent. Biological activity was measured using a cytotoxicity assay of the human A2780 ovarian cancer cell line treated with a range of compound concentrations. Nitrogen-based substitutions on the terminal aryl group caused similar, but slightly reduced efficacies and potencies. Exceptions were systems that had a nitro group at the para position, the potencies of which were better than that of SHetA2 with efficacies that were only slightly reduced compared to SHetA2. Similarly, the potency of the system with a para dimethylamino group was greater than that of SHetA2. However, a 30% reduction in efficacy compared to SHetA2 was noted. While specific members with the 4-atom acrylamide linker did exhibit excellent potency, the efficacy was slightly below that of SHetA2. Thus, a gradient of activities was observed as the substituent on the aryl ring was altered. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 50 条
  • [1] Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780
    Nammalwar, Baskar
    Bunce, Richard A.
    Berlin, K. Darrell
    Benbrook, Doris M.
    Toal, Coralee
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 170 : 16 - 27
  • [2] Synthesis and Characterization of Asparaginase Bound Silver Nanocomposite Against Ovarian Cancer Cell Line A2780 and Lung Cancer Cell Line A549
    Baskar, G.
    George, Garrick Bikku
    Chamundeeswari, M.
    JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS, 2017, 27 (01) : 87 - 94
  • [3] Synthesis and Characterization of Asparaginase Bound Silver Nanocomposite Against Ovarian Cancer Cell Line A2780 and Lung Cancer Cell Line A549
    G. Baskar
    Garrick Bikku George
    M. Chamundeeswari
    Journal of Inorganic and Organometallic Polymers and Materials, 2017, 27 : 87 - 94
  • [4] Growth Inhibition and Apoptosis Inducing Mechanisms of Curcumin on Human Ovarian Cancer Cell Line A2780
    郑丽端
    童强松
    吴翠环
    Chinese Journal of Integrative Medicine, 2006, (02) : 126 - 131
  • [5] Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line A2780
    Zheng L.-D.
    Tong Q.-S.
    Wu C.-H.
    Chinese Journal of Integrative Medicine, 2006, 12 (2) : 126 - 131
  • [6] INDUCTION OF RESISTANCE TO 2',2'-DIFLUORODEOXYCYTIDINE IN THE HUMAN OVARIAN-CANCER CELL-LINE A2780
    VANHAPEREN, VWTR
    VEERMAN, G
    ERIKSSON, S
    STEGMANN, APA
    PETERS, GJ
    SEMINARS IN ONCOLOGY, 1995, 22 (04) : 35 - 41
  • [7] ATYPICAL MULTIDRUG-RESISTANCE IN HUMAN OVARIAN-CANCER CELL-LINE A2780 SELECTED FOR RESISTANCE TO DOXORUBICIN (A2780 DX3)
    CIMOLI, G
    NOVIELLO, E
    MAZZONI, A
    DESESSA, F
    VALENTI, M
    PARODI, S
    ROVINI, E
    RUSSO, P
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (03) : 155 - 163
  • [8] Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line
    Januchowski, Radoslaw
    Zawierucha, Piotr
    Rucinski, Marcin
    Andrzejewska, Malgorzata
    Wojtowicz, Karolina
    Nowicki, Michal
    Zabel, Maciej
    BIOMEDICINE & PHARMACOTHERAPY, 2014, 68 (04) : 447 - 453
  • [9] Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line
    Viscarra, Tamara
    Buchegger, Kurt
    Jofre, Ignacio
    Riquelme, Ismael
    Zanella, Louise
    Abanto, Michel
    Parker, Alyssa C.
    Piccolo, Stephen R.
    Roa, Juan Carlos
    Ili, Carmen
    Brebi, Priscilla
    BIOLOGICAL RESEARCH, 2019, 52 : 13
  • [10] Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line
    Tamara Viscarra
    Kurt Buchegger
    Ignacio Jofre
    Ismael Riquelme
    Louise Zanella
    Michel Abanto
    Alyssa C. Parker
    Stephen R. Piccolo
    Juan Carlos Roa
    Carmen Ili
    Priscilla Brebi
    Biological Research, 52